

# Robert J Hamilton

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5609464/publications.pdf>

Version: 2024-02-01

204  
papers

5,219  
citations

116194

36  
h-index

134545

62  
g-index

210  
all docs

210  
docs citations

210  
times ranked

8194  
citing authors

#	ARTICLE	IF	CITATIONS
1	Applicant perceptions of virtual interviews for society of urologic oncology fellowships during the COVID-19 pandemic. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2023, 41, 65-68.	0.8	7
2	Circumcision and Risk of HIV among Males from Ontario, Canada. <i>Journal of Urology</i> , 2022, 207, 424-430.	0.2	5
3	Management of stage I testicular cancer. <i>Current Opinion in Urology</i> , 2022, 32, 17-23.	0.9	4
4	Robotic RPLND for stage IIA/B nonseminoma: the Princess Margaret Experience. <i>World Journal of Urology</i> , 2022, 40, 335-342.	1.2	6
5	Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 755-761.	2.0	14
6	Pharmacogenomics of cisplatin-induced neurotoxicities: Hearing loss, tinnitus, and peripheral sensory neuropathy. <i>Cancer Medicine</i> , 2022, 11, 2801-2816.	1.3	14
7	Factors Associated with Stent Change and Prognosis in Patients with Malignant Ureteral Obstruction. <i>Journal of Endourology</i> , 2022, 36, 1083-1090.	1.1	2
8	PSMA PET/CT guided intensification of therapy in patients at risk of advanced prostate cancer (PATRON): a pragmatic phase III randomized controlled trial. <i>BMC Cancer</i> , 2022, 22, 251.	1.1	5
9	Minimally invasive retroperitoneal lymph node dissection for men with testis cancer: a retrospective cohort study of safety and feasibility. <i>World Journal of Urology</i> , 2022, 40, 1505-1512.	1.2	12
10	Semen and serum platinum levels in cisplatin-treated survivors of germ cell cancer. <i>Cancer Medicine</i> , 2022, 11, 728-734.	1.3	4
11	Case "Intra-abdominal metastases following ventriculoperitoneal shunt insertion for primary intracranial germ cell tumor. <i>Canadian Urological Association Journal</i> , 2022, 16, .	0.3	0
12	Implementing and Evaluating the Impact of BoneRx: A Healthy Bone Prescription for Men with Prostate Cancer Initiating Androgen Deprivation Therapy. <i>Journal of Clinical Medicine</i> , 2022, 11, 2703.	1.0	5
13	Prostate biopsy in the era of MRI-targeting: towards a judicious use of additional systematic biopsy. <i>European Radiology</i> , 2022, 32, 7544-7554.	2.3	8
14	Safety of Minimizing Intensity of Follow-up on Active Surveillance for Clinical Stage I Testicular Germ Cell Tumors. <i>European Urology Open Science</i> , 2022, 40, 46-53.	0.2	6
15	Elevated HCG and retroperitoneal adenopathy after clomiphene therapy for infertility. <i>BMJ Case Reports</i> , 2022, 15, e249766.	0.2	0
16	Association Study between Polymorphisms in DNA Methylation-Related Genes and Testicular Germ Cell Tumor Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1769-1779.	1.1	4
17	Statins and prostate cancer "hype or hope? The epidemiological perspective. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 641-649.	2.0	14
18	Statins and prostate cancer "hype or hope? The biological perspective. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 650-656.	2.0	7

#	ARTICLE	IF	CITATIONS
19	5-Alpha Reductase Inhibitor Use and Prostate Cancer Prevention: A Victim of the Times?. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1259-1260.	1.1	1
20	Natural History of Renal Angiomyolipoma Favors Surveillance as an Initial Approach. <i>European Urology Focus</i> , 2021, 7, 582-588.	1.6	10
21	Association between metformin medication, genetic variation and prostate cancer risk. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 96-105.	2.0	10
22	Integrated Expression of Circulating miR375 and miR371 to Identify Teratoma and Active Germ Cell Malignancy Components in Malignant Germ Cell Tumors. <i>European Urology</i> , 2021, 79, 16-19.	0.9	36
23	Response to the Letter to the Editor: "Association between metformin medication, genetic variation and prostate cancer risk" genotyping and patient categorization, do they matter?. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 280-280.	2.0	1
24	Utility of Serum miR-371a-3p in Predicting Relapse on Surveillance in Patients with Clinical Stage I Testicular Germ Cell Cancer. <i>European Urology Oncology</i> , 2021, 4, 483-491.	2.6	39
25	Hospital-level Effects Contribute to Variations in Prostate Cancer Quality of Care. <i>European Urology Oncology</i> , 2021, 4, 494-497.	2.6	3
26	Long-term Surveillance of Patients with Complete Response Following Chemotherapy for Metastatic Nonseminomatous Germ Cell Tumor. <i>European Urology Oncology</i> , 2021, 4, 289-296.	2.6	13
27	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. <i>Nature Genetics</i> , 2021, 53, 65-75.	9.4	264
28	Preferences for exercise and physical activity support in adolescent and young adult cancer survivors: a cross-sectional survey. <i>Supportive Care in Cancer</i> , 2021, 29, 4113-4127.	1.0	19
29	Real-World Use of Androgen-Deprivation Therapy: Intensification Among Older Canadian Men With de Novo Metastatic Prostate Cancer. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab082.	1.4	17
30	Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 532-541.	2.0	16
31	Polygenic hazard score is associated with prostate cancer in multi-ethnic populations. <i>Nature Communications</i> , 2021, 12, 1236.	5.8	40
32	Quantitative Prostate MRI Analysis Following Fluvastatin Therapy for Localized Prostate Cancer - A Pilot Study. <i>Canadian Association of Radiologists Journal</i> , 2021, 72, 750-758.	1.1	0
33	Real-world utilization of docetaxel among men with <i>de novo</i> metastatic castration-sensitive prostate cancer: A population-based study in men aged 66 or older.. <i>Journal of Clinical Oncology</i> , 2021, 39, 47-47.	0.8	1
34	Benefit of a more extended pelvic lymph node dissection among patients undergoing radical prostatectomy for localized prostate cancer: A causal mediation analysis. <i>Prostate</i> , 2021, 81, 286-294.	1.2	4
35	Geographic variation in systemic therapy in men age 66 years and older with de novo metastatic castration-sensitive prostate cancer: A population-based study in a single payer health-system.. <i>Journal of Clinical Oncology</i> , 2021, 39, 50-50.	0.8	1
36	Salvage lymph node dissection for prostate-specific membrane antigen (PSMA) positron emission tomography (PET)-identified oligometastatic disease. <i>Canadian Urological Association Journal</i> , 2021, 15, E545-E552.	0.3	3

#	ARTICLE	IF	CITATIONS
37	Pathologic concordance of resected metastatic nonseminomatous germ cell tumors in the chest. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021, 161, 856-868.e1.	0.4	5
38	MRI-guided Focused Ultrasound Ablation for Localized Intermediate-Risk Prostate Cancer: Early Results of a Phase II Trial. <i>Radiology</i> , 2021, 298, 695-703.	3.6	33
39	The Association Between Statin Use and Outcomes in Patients Initiating Androgen Deprivation Therapy. <i>European Urology</i> , 2021, 79, 446-452.	0.9	24
40	Virtual care for prostate cancer survivorship: protocol for an evaluation of a nurse-led algorithm-enhanced virtual clinic implemented at five cancer centres across Canada. <i>BMJ Open</i> , 2021, 11, e045806.	0.8	12
41	Integration of a polygenic risk score of kidney function with cumulative cisplatin dose and time variables for the prediction of serum platinum levels.. <i>Journal of Clinical Oncology</i> , 2021, 39, 12063-12063.	0.8	1
42	Factors associated with use of medications for anxiety and depression in testicular cancer survivors after cisplatin-based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, 5025-5025.	0.8	2
43	Identification of 22 susceptibility loci associated with testicular germ cell tumors. <i>Nature Communications</i> , 2021, 12, 4487.	5.8	27
44	Defining oligometastatic hormone sensitive prostate cancer and clinically significant outcomes: Implications on clinical trials?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 431.e1-431.e8.	0.8	2
45	Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis. <i>European Urology</i> , 2021, 80, 374-382.	0.9	49
46	Circulating MicroRNAs, the Next-Generation Serum Biomarkers in Testicular Germ Cell Tumours: A Systematic Review. <i>European Urology</i> , 2021, 80, 456-466.	0.9	60
47	The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Metastatic Testicular Cancer. <i>Current Oncology</i> , 2021, 28, 107-114.	0.9	10
48	Back to the Future—Moving Forward for Testicular Cancer Survivors. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz082.	1.4	3
49	Salvage radical prostatectomy following focal therapy: functional and oncological outcomes. <i>BJU International</i> , 2020, 125, 525-530.	1.3	21
50	Simultaneous Vs Sequential Retroperitoneal, Thoracic and Cervical Resection of Post Chemotherapy Residual Masses in Patients With Metastatic Nonseminomatous Germ Cell Tumors of the Testis. <i>Urology</i> , 2020, 138, 69-76.	0.5	3
51	Psychological morbidity associated with prostate cancer: Rates and predictors of depression in the RADICAL PC study. <i>Canadian Urological Association Journal</i> , 2020, 15, 181-186.	0.3	13
52	Clinical dilemmas in local and regional testis cancer. <i>Canadian Urological Association Journal</i> , 2020, 15, E58-E64.	0.3	1
53	Virtual care models for cancer survivorship. <i>Npj Digital Medicine</i> , 2020, 3, 113.	5.7	25
54	The CHEK2 Variant C.349A>G Is Associated with Prostate Cancer Risk and Carriers Share a Common Ancestor. <i>Cancers</i> , 2020, 12, 3254.	1.7	16

#	ARTICLE	IF	CITATIONS
55	[ <sup>18</sup> F]DCFPyL PET-MRI/CT for unveiling a molecularly defined oligorecurrent prostate cancer state amenable for curative-intent ablative therapy: study protocol for a phase II trial. <i>BMJ Open</i> , 2020, 10, e035959.	0.8	8
56	A Canadian approach to the regionalization of testis cancer: A review. <i>Canadian Urological Association Journal</i> , 2020, 14, 346-351.	0.3	0
57	Psychological distress associated with active surveillance in patients younger than 70 with a small renal mass. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 603.e17-603.e25.	0.8	14
58	Two cases - Orthostatic hypotension following retroperitoneal lymph node dissection. <i>Canadian Urological Association Journal</i> , 2020, 14, E468-E470.	0.3	0
59	A pilot window-of-opportunity study of preoperative fluvastatin in localized prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 630-637.	2.0	31
60	Controversies in the management of clinical stage 1 testis cancer. <i>Canadian Urological Association Journal</i> , 2020, 14, E537-E542.	0.3	4
61	Discrepancy in pathology reports upon second review of radical orchiectomy specimens for testicular germ cell tumors. <i>Canadian Urological Association Journal</i> , 2020, 14, 411-415.	0.3	6
62	The long-term outcomes of Gleason grade groups 2 and 3 prostate cancer managed by active surveillance: Results from a large population-based cohort. <i>Canadian Urological Association Journal</i> , 2020, 14, 174-181.	0.3	13
63	Active surveillance in stage 1 disease. <i>Current Opinion in Urology</i> , 2020, 30, 245-250.	0.9	10
64	Zero, Some Chemotherapy Game in Early-Stage Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2020, 38, 2214-2215.	0.8	2
65	Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies. <i>Canadian Urological Association Journal</i> , 2020, 15, E307-E322.	0.3	10
66	Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies – Executive summary. <i>Canadian Urological Association Journal</i> , 2020, 15, 159-61.	0.3	2
67	Does Time Spent on Active Surveillance Adversely Affect the Pathological and Oncologic Outcomes in Patients Undergoing Delayed Radical Prostatectomy?. <i>Journal of Urology</i> , 2020, 204, 476-482.	0.2	7
68	A Prospective Randomized Controlled Trial of Irrigation “Bag Squeeze” to Manage Pain for Patients Undergoing Flexible Cystoscopy. <i>Journal of Urology</i> , 2020, 204, 1012-1018.	0.2	9
69	Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?. <i>Journal of Urology</i> , 2020, 204, 1187-1194.	0.2	9
70	Clinical and Genome-Wide Analysis of Multiple Severe Cisplatin-Induced Neurotoxicities in Adult-Onset Cancer Survivors. <i>Clinical Cancer Research</i> , 2020, 26, 6550-6558.	3.2	9
71	Primary analysis of a phase II study of metastasis-directed ablative therapy to PSMA ( <sup>18</sup> F-DCFPyL) PET-MR/CT defined oligorecurrent prostate cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5553-5553.	0.8	1
72	Persistence of platinum in semen of cisplatin-treated survivors of advanced testicular cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5056-5056.	0.8	0

#	ARTICLE	IF	CITATIONS
73	Reply by Authors. <i>Journal of Urology</i> , 2020, 204, 1194-1194.	0.2	0
74	Clinical and Genome-Wide Analysis of Serum Platinum Levels after Cisplatin-Based Chemotherapy. <i>Clinical Cancer Research</i> , 2019, 25, 5913-5924.	3.2	16
75	The Role of Robotic Retroperitoneal Lymph Node Dissection for Testis Cancer. <i>Urologic Clinics of North America</i> , 2019, 46, 409-417.	0.8	9
76	Diabetes and kidney cancer survival in patients undergoing nephrectomy: A Canadian multi-center, propensity score analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 576.e11-576.e16.	0.8	3
77	Optimal Management of High-risk Stage I Nonseminomatous Germ Cell Tumor: Surveillance is the Preferred Option. <i>European Urology Focus</i> , 2019, 5, 702-703.	1.6	4
78	Developing a Highly Specific Biomarker for Germ Cell Malignancies: Plasma miR371 Expression Across the Germ Cell Malignancy Spectrum. <i>Journal of Clinical Oncology</i> , 2019, 37, 3090-3098.	0.8	81
79	Re: Adam C. Calaway, Lawrence H. Einhorn, Timothy A. Masterson, Richard S. Foster, Clint Cary. Adverse Surgical Outcomes Associated with Robotic Retroperitoneal Lymph Node Dissection Among Patients with Testicular Cancer. <i>Eur Urol</i> 2019;76:607-609. <i>European Urology</i> , 2019, 76, e139-e140.	0.9	4
80	Shared heritability and functional enrichment across six solid cancers. <i>Nature Communications</i> , 2019, 10, 431.	5.8	88
81	Long-term oncological outcomes of patients with paratesticular sarcoma. <i>BJU International</i> , 2019, 124, 801-810.	1.3	13
82	Treatment of Relapse of Clinical Stage I Nonseminomatous Germ Cell Tumors on Surveillance. <i>Journal of Clinical Oncology</i> , 2019, 37, 1919-1926.	0.8	47
83	An actionable sterol-regulated feedback loop modulates statin sensitivity in prostate cancer. <i>Molecular Metabolism</i> , 2019, 25, 119-130.	3.0	55
84	Clinical and Genome-wide Analysis of Cisplatin-induced Tinnitus Implicates Novel Ototoxic Mechanisms. <i>Clinical Cancer Research</i> , 2019, 25, 4104-4116.	3.2	27
85	Extraprostatic Extension in Core Biopsies Epitomizes High-risk but Locally Treatable Prostate Cancer. <i>European Urology Oncology</i> , 2019, 2, 88-96.	2.6	7
86	Management algorithms for prostate-specific antigen progression in prostate cancer: Biochemical recurrence after definitive therapy and progression to non-metastatic castrate-resistant prostate cancer. <i>Canadian Urological Association Journal</i> , 2019, 13, 420-426.	0.3	9
87	Are there differences between de novo and secondary upper tract urothelial carcinoma tumours?. <i>Canadian Urological Association Journal</i> , 2019, 13, E292-E299.	0.3	0
88	Chemotherapy intensification for first-line treatment of poor-prognosis metastatic germ cell cancer is not yet ready for prime time. <i>Canadian Urological Association Journal</i> , 2019, 14, 48-49.	0.3	0
89	Detection of Relapse by Low-dose Computed Tomography During Surveillance in Stage I Testicular Germ Cell Tumours. <i>European Urology Oncology</i> , 2019, 2, 437-442.	2.6	11
90	Identification and Validation Model for Informative Liquid Biopsy-Based microRNA Biomarkers: Insights from Germ Cell Tumor In Vitro, In Vivo and Patient-Derived Data. <i>Cells</i> , 2019, 8, 1637.	1.8	73

#	ARTICLE	IF	CITATIONS
91	Metformin Use and Kidney Cancer Survival Outcomes. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 275-284.	0.6	6
92	Germ Cell Testicular Tumors—Contemporary Diagnosis, Staging and Management of Localized and Advanced disease. <i>Urology</i> , 2019, 125, 8-19.	0.5	19
93	Obesity, risk of biochemical recurrence, and prostate-specific antigen doubling time after radical prostatectomy: results from the SEARCH database. <i>BJU International</i> , 2019, 124, 69-75.	1.3	15
94	Combined genetic and epigenetic alterations of the <i>TERT</i> promoter affect clinical and biological behavior of bladder cancer. <i>International Journal of Cancer</i> , 2019, 144, 1676-1684.	2.3	57
95	Testicular Cancer Biomarkers: A Role for Precision Medicine in Testicular Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e176-e183.	0.9	37
96	Circulating Metabolic Biomarkers of Screen-Detected Prostate Cancer in the ProtecT Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 208-216.	1.1	21
97	Adverse Health Outcomes in Relationship to Hypogonadism After Chemotherapy: A Multicenter Study of Testicular Cancer Survivors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 459-468.	2.3	13
98	Serum miRNA Predicts Viable Disease after Chemotherapy in Patients with Testicular Nonseminoma Germ Cell Tumor. <i>Journal of Urology</i> , 2018, 200, 126-135.	0.2	107
99	A New Model to Predict Benign Histology in Residual Retroperitoneal Masses After Chemotherapy in Nonseminoma. <i>European Urology Focus</i> , 2018, 4, 995-1001.	1.6	26
100	Changing Trends for Suicidal Death in Patients With Bladder Cancer: A 40+ Year Population-level Analysis. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 206-212.e1.	0.9	28
101	Active Surveillance for Stage I Testicular Cancer: A Four-decade-old Experiment Proven Correct. <i>European Urology</i> , 2018, 73, 908-909.	0.9	3
102	Lymphadenectomy in Gleason 7 prostate cancer: Adherence to guidelines and effect on clinical outcomes. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 13.e11-13.e18.	0.8	3
103	Medication use and kidney cancer survival: A population-based study. <i>International Journal of Cancer</i> , 2018, 142, 1776-1785.	2.3	9
104	Germline BRCA mutation in male carriers—ripe for precision oncology?. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 48-56.	2.0	13
105	Testosterone Responders to Continuous Androgen Deprivation Therapy Show Considerable Variations in Testosterone Levels on Followup: Implications for Clinical Practice. <i>Journal of Urology</i> , 2018, 199, 251-256.	0.2	3
106	Does perioperative chemotherapy improve survival in upper tract urothelial carcinoma? A population based analysis. <i>Oncotarget</i> , 2018, 9, 18797-18810.	0.8	10
107	Applying Radiomics to Predict Pathology of Postchemotherapy Retroperitoneal Nodal Masses in Germ Cell Tumors. <i>JCO Clinical Cancer Informatics</i> , 2018, 2, 1-12.	1.0	21
108	Challenges Interpreting Chemoprevention Studies Using Observational Data. <i>Journal of Clinical Oncology</i> , 2018, 36, 628-629.	0.8	5

#	ARTICLE	IF	CITATIONS
109	Another dimension to the understanding of local therapy for metastatic prostate cancer. Canadian Urological Association Journal, 2018, 13, 182-183.	0.3	0
110	DNA hypermethylation within TERT promoter upregulates TERT expression in cancer. Journal of Clinical Investigation, 2018, 129, 223-229.	3.9	130
111	A novel predictor of clinical progression in patients on active surveillance for prostate cancer. Canadian Urological Association Journal, 2018, 13, 250-255.	0.3	3
112	Conditional risk of relapse in patients with germ cell testicular tumors. Current Opinion in Urology, 2018, 28, 454-460.	0.9	2
113	Germline variation at 8q24 and prostate cancer risk in men of European ancestry. Nature Communications, 2018, 9, 4616.	5.8	43
114	Replacing surveillance cystoscopy with urinary biomarkers in followup of patients with non-muscle-invasive bladder cancer: Patients' and urologic oncologists' perspectives. Canadian Urological Association Journal, 2018, 12, E210-8.	0.3	7
115	Dissecting the Evolving Risk of Relapse over Time in Surveillance for Testicular Cancer. Advances in Urology, 2018, 2018, 1-7.	0.6	4
116	Evaluation of an Aggressive Prostate Biopsy Strategy in Men Younger than 50 Years. Journal of Urology, 2018, 200, 1056-1061.	0.2	2
117	Gene expression signatures prognostic for relapse in stage I testicular germ cell tumours. BJU International, 2018, 122, 814-822.	1.3	8
118	Statin use and time to progression in men on active surveillance for prostate cancer. Prostate Cancer and Prostatic Diseases, 2018, 21, 509-515.	2.0	7
119	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nature Genetics, 2018, 50, 928-936.	9.4	652
120	Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. Nature Communications, 2018, 9, 2256.	5.8	88
121	Variants in <i>WFS1</i> and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity. Clinical Cancer Research, 2017, 23, 3325-3333.	3.2	65
122	Effect of statins as a secondary chemopreventive agent among individuals with non-muscle-invasive bladder cancer: A population-based analysis. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 342-348.	0.8	17
123	Statin use and kidney cancer survival outcomes: A systematic review and meta-analysis. Cancer Treatment Reviews, 2017, 52, 105-116.	3.4	53
124	Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer. Clinical Cancer Research, 2017, 23, 5757-5768.	3.2	63
125	Critical appraisal of the application of propensity score methods in the urology literature. BJU International, 2017, 120, 873-880.	1.3	9
126	Development and external validation of a biopsy-derived nomogram to predict risk of ipsilateral extraprostatic extension. BJU International, 2017, 120, 76-82.	1.3	23



#	ARTICLE	IF	CITATIONS
127	Metastatic renal cell carcinoma: Patterns and predictors of metastasesâ€”A contemporary population-based series. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 661.e7-661.e14.	0.8	76
128	The Association Between Vasectomy and Prostate Cancer. <i>JAMA Internal Medicine</i> , 2017, 177, 1273.	2.6	31
129	PD53-07 CONDITIONAL RISK OF RELAPSE IN 3,601 PATIENTS MANAGED WITH SURVEILLANCE FOR STAGE I TESTICULAR CANCER. <i>Journal of Urology</i> , 2017, 197, .	0.2	1
130	Medication use and kidney cancer risk: A population-based study. <i>European Journal of Cancer</i> , 2017, 83, 203-210.	1.3	11
131	Creation and internal validation of a biopsy avoidance prediction tool to aid in the choice of diagnostic approach in patients with prostate cancer suspicion. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 604.e17-604.e24.	0.8	2
132	Reply from Authors re: Peter Albers. Surveillance of Patients with Clinical Stage I Testis Cancer is Safe and Will Remain Unchanged. <i>Eur Urol</i> 2017;71:130â€”131.. <i>European Urology</i> , 2017, 71, 131-132.	0.9	1
133	The current evidence on statin use and prostate cancer prevention: are we there yet?. <i>Nature Reviews Urology</i> , 2017, 14, 107-119.	1.9	111
134	Diabetes and kidney cancer outcomes: a propensity score analysis. <i>Endocrine</i> , 2017, 55, 470-477.	1.1	8
135	Metformin Use and Kidney Cancer Outcomes in Patients With Diabetes: A Propensity Score Analysis. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 300-305.	0.9	17
136	Conditional Risk of Relapse in Surveillance for Clinical Stage I Testicular Cancer. <i>European Urology</i> , 2017, 71, 120-127.	0.9	54
137	Making Sense of the Statinâ€”Prostate Cancer Relationship: Is It Time for a Randomized Controlled Trial?. <i>European Urology Focus</i> , 2017, 3, 221-222.	1.6	3
138	Recommendations for followup of stage I and II seminoma: The Princess Margaret Cancer Centre approach. <i>Canadian Urological Association Journal</i> , 2017, 12, 59-66.	0.3	12
139	Assessment of a prognostic model, PSA metrics and toxicities in metastatic castrate resistant prostate cancer using data from Project Data Sphere (PDS). <i>PLoS ONE</i> , 2017, 12, e0170544.	1.1	11
140	Retroperitoneal hematoma following radical orchiectomy: Two cases. <i>Canadian Urological Association Journal</i> , 2017, 11, 35.	0.3	3
141	Case: Bacillus Calmette-Guerin (BCG)-induced Reiter syndrome with an attempt at repeat BCG induction. <i>Canadian Urological Association Journal</i> , 2017, 12, E37-9.	0.3	7
142	Modern-day prostate cancer is not meaningfully associated with lower urinary tract symptoms: Analysis of a propensity score-matched cohort. <i>Canadian Urological Association Journal</i> , 2017, 11, 41.	0.3	11
143	The value of complementing administrative data with abstracted information on smoking and obesity: A study in kidney cancer. <i>Canadian Urological Association Journal</i> , 2017, 11, 167.	0.3	6
144	28-year late spermatic cord relapse of a testicular non-seminomatous germ cell tumour, managed robotically. <i>Canadian Urological Association Journal</i> , 2016, 10, 257.	0.3	1

#	ARTICLE	IF	CITATIONS
145	The association between institution at orchiectomy and outcomes on active surveillance for clinical stage I germ cell tumours. Canadian Urological Association Journal, 2016, 10, 204.	0.3	10
146	Randomized controlled trials in testicular cancer: A demographic and quality assessment. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 60.e7-60.e13.	0.8	1
147	Medication use and survival in diabetic patients with kidney cancer: A population-based cohort study. Pharmacological Research, 2016, 113, 468-474.	3.1	19
148	Statin use and kidney cancer outcomes: A propensity score analysis. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 487.e1-487.e6.	0.8	16
149	Stricter Active Surveillance Criteria for Prostate Cancer do Not Result in Significantly Better Outcomes: A Comparison of Contemporary Protocols. Journal of Urology, 2016, 196, 1645-1650.	0.2	19
150	Vasectomy and risk of prostate cancer: population based matched cohort study. BMJ, The, 2016, 355, i5546.	3.0	18
151	Hematologic Parameters to Predict Small Renal Mass Biopsy Pathology. Clinical Genitourinary Cancer, 2016, 14, 226-230.	0.9	2
152	Influence of Metabolic Syndrome on Prostate Cancer Stage, Grade, and Overall Recurrence Risk in Men Undergoing Radical Prostatectomy. Urology, 2016, 93, 77-85.	0.5	31
153	A cancer specific hypermethylation signature of the TERT promoter predicts biochemical relapse in prostate cancer: a retrospective cohort study. Oncotarget, 2016, 7, 57726-57736.	0.8	55
154	The initiation of a multidisciplinary bladder cancer clinic and the uptake of neoadjuvant chemotherapy: A time-series analysis. Canadian Urological Association Journal, 2016, 10, 25.	0.3	17
155	Gene-expression signatures as prognostic for relapse in stage I testicular germ cell tumors (TGCT).. Journal of Clinical Oncology, 2016, 34, 493-493.	0.8	1
156	MP10-10 OUTCOMES OF PROGRESSION ON SURVEILLANCE FOR CLINICAL STAGE I NONSEMINOMATOUS GERM CELL TUMOURS. Journal of Urology, 2015, 193, .	0.2	1
157	MP73-04 THE ASSOCIATION BETWEEN STATIN USE AND OUTCOMES IN PATIENTS INITIATING ANDROGEN DEPRIVATION THERAPY. Journal of Urology, 2015, 193, .	0.2	2
158	Is PSA related to serum cholesterol and does the relationship differ between black and white men?. Prostate, 2015, 75, 1877-1885.	1.2	12
159	Is orchiectomy always necessary in retroperitoneal extragonadal germ cell tumours?. Canadian Urological Association Journal, 2015, 9, 385.	0.3	1
160	Large Retroperitoneal Lymphadenopathy As a Predictor of Venous Thromboembolism in Patients With Disseminated Germ Cell Tumors Treated With Chemotherapy. Journal of Clinical Oncology, 2015, 33, 582-587.	0.8	50
161	The effect of metformin on cancer-specific survival outcomes in diabetic patients undergoing radical cystectomy for urothelial carcinoma of the bladder. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 386.e7-386.e13.	0.8	31
162	Impact of the U.S. Preventive Services Task Force Recommendations against Prostate Specific Antigen Screening on Prostate Biopsy and Cancer Detection Rates. Journal of Urology, 2015, 193, 1519-1524.	0.2	90

#	ARTICLE	IF	CITATIONS
163	Lymph Node Yield in Primary Retroperitoneal Lymph Node Dissection for Nonseminoma Germ Cell Tumors. <i>Journal of Urology</i> , 2015, 194, 386-391.	0.2	23
164	Dissecting the Association Between Metabolic Syndrome and Prostate Cancer Risk: Analysis of a Large Clinical Cohort. <i>European Urology</i> , 2015, 67, 64-70.	0.9	91
165	The association between statin use and outcomes in patients initiating androgen deprivation therapy.. <i>Journal of Clinical Oncology</i> , 2015, 33, 145-145.	0.8	2
166	Outcomes of progression on surveillance for clinical stage I nonseminomatous germ cell tumours (NSGCT).. <i>Journal of Clinical Oncology</i> , 2015, 33, 377-377.	0.8	1
167	Health-related quality of life in robotic versus open radical prostatectomy. <i>Canadian Urological Association Journal</i> , 2015, 9, 179.	0.3	9
168	Project data sphere (PDS) in prostate cancer: A first look including concomitant medication use.. <i>Journal of Clinical Oncology</i> , 2015, 33, 204-204.	0.8	0
169	Concordance between transrectal ultrasound guided biopsy results and radical prostatectomy final pathology: Are we getting better at predicting final pathology?. <i>Canadian Urological Association Journal</i> , 2014, 8, 47.	0.3	11
170	Obesity Is Associated With Larger Prostate Volume but not With Worse Urinary Symptoms: Analysis of a Large Multiethnic Cohort. <i>Urology</i> , 2014, 83, 81-87.	0.5	22
171	The Association between Statin Medication and Progression after Surgery for Localized Renal Cell Carcinoma. <i>Journal of Urology</i> , 2014, 191, 914-919.	0.2	39
172	A Negative Confirmatory Biopsy Among Men on Active Surveillance for Prostate Cancer Does Not Protect Them from Histologic Grade Progression. <i>European Urology</i> , 2014, 66, 406-413.	0.9	36
173	Chemoprevention of Prostate Cancer. <i>Annual Review of Medicine</i> , 2014, 65, 111-123.	5.0	12
174	Metformin for Castrate-resistant Prostate Cancer: Learning More About an Old Dog's New Tricks. <i>European Urology</i> , 2014, 66, 475-477.	0.9	4
175	Chemoprevention of prostate cancer: what have we learned?. <i>Trends in Urology &amp; Men's Health</i> , 2014, 5, 25-29.	0.2	0
176	The Impact of the Use of Aspirin and Other Nonsteroidal Anti-inflammatory Drugs on the Risk of Prostate Cancer Detection on Biopsy. <i>Urology</i> , 2014, 84, 1073-1080.	0.5	2
177	Obesity Is Associated with Risk of Progression for Low-risk Prostate Cancers Managed Expectantly. <i>European Urology</i> , 2014, 66, 841-848.	0.9	56
178	The Importance of Surgeon Characteristics on Impacting Oncologic Outcomes for Patients Undergoing Radical Cystectomy. <i>Journal of Urology</i> , 2014, 192, 714-720.	0.2	22
179	Effect of concomitant medication use on outcomes of treatment and placebo arms of the COU-AA-301 and COU-AA-302 studies of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2014, 32, e16045-e16045.	0.8	4
180	Essential experimental steps and estimates of renal carcinoma initiating cells.. <i>Journal of Clinical Oncology</i> , 2014, 32, 11127-11127.	0.8	0

#	ARTICLE	IF	CITATIONS
181	Obesity Is Associated with Increased Prostate Growth and Attenuated Prostate Volume Reduction by Dutasteride. <i>European Urology</i> , 2013, 63, 1115-1121.	0.9	49
182	Using 5-ARIs: When is it appropriate?. <i>Canadian Urological Association Journal</i> , 2013, 7, 454.	0.3	0
183	VHL-mutant renal cell carcinomas contain cancer cells with mesenchymal phenotypes.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4568-4568.	0.8	2
184	5 $\alpha$ -Reductase Inhibitors: Preventing the Treatable. <i>European Urology</i> , 2012, 62, 242-244.	0.9	6
185	995 ANALYSIS OF STATIN MEDICATION, GENETIC VARIATION AND PROSTATE CANCER OUTCOMES. <i>Journal of Urology</i> , 2011, 185, .	0.2	2
186	5 $\alpha$ -reductase inhibitors and prostate cancer prevention: where do we turn now?. <i>BMC Medicine</i> , 2011, 9, 105.	2.3	26
187	Race, healthcare access and physician trust among prostate cancer patients. <i>Cancer Causes and Control</i> , 2010, 21, 31-40.	0.8	51
188	Statin medication use and the risk of biochemical recurrence after radical prostatectomy. <i>Cancer</i> , 2010, 116, 3389-3398.	2.0	112
189	Association between Statins and Prostate Tumor Inflammatory Infiltrate in Men Undergoing Radical Prostatectomy. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 722-728.	1.1	47
190	Knowledge and Use of Finasteride for the Prevention of Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 2164-2171.	1.1	34
191	Re: Prostate-Specific Antigen: A Misused and Maligned Prostate Cancer Biomarker. <i>Journal of the National Cancer Institute</i> , 2009, 101, 611-612.	3.0	2
192	Rationale for statins in the chemoprevention of prostate cancer. <i>Current Urology Reports</i> , 2008, 9, 189-196.	1.0	23
193	Perceived family history risk and symptomatic diagnosis of prostate cancer. <i>Cancer</i> , 2008, 113, 2180-2187.	2.0	21
194	Body Mass Index, Prostate-Specific Antigen, and Digital Rectal Examination Findings Among Participants in a Prostate Cancer Screening Clinic. <i>Urology</i> , 2008, 71, 787-791.	0.5	41
195	Limitations of Prostate Specific Antigen Doubling Time Following Biochemical Recurrence After Radical Prostatectomy: Results From the SEARCH Database. <i>Journal of Urology</i> , 2008, 179, 1785-1790.	0.2	17
196	The Influence of Statin Medications on Prostate-specific Antigen Levels. <i>Journal of the National Cancer Institute</i> , 2008, 100, 1511-1518.	3.0	145
197	Review of recent evidence in support of a role for statins in the prevention of prostate cancer. <i>Current Opinion in Urology</i> , 2008, 18, 333-339.	0.9	35
198	Obesity-Related Plasma Hemodilution and PSA Concentration Among Men With Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 2275.	3.8	291

#	ARTICLE	IF	CITATIONS
199	Laparoscopic Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ-Cell Tumors: Current Status. <i>Urologic Clinics of North America</i> , 2007, 34, 159-169.	0.8	10
200	Hidden barriers between knowledge and behavior. <i>Cancer</i> , 2007, 109, 1599-1606.	2.0	73
201	Race, biochemical disease recurrence, and prostate-specific antigen doubling time after radical prostatectomy. <i>Cancer</i> , 2007, 110, 2202-2209.	2.0	62
202	An efficient solution to the retained Foley catheter. <i>Urology</i> , 2006, 68, 1109-1111.	0.5	4
203	The impact of introducing laparoscopic radical prostatectomy on surgical wait times for prostate cancer. <i>Canadian Journal of Urology</i> , 2006, 13 Suppl 3, 25-9.	0.0	1
204	Internet-Based Continuing Medical Education in Otolaryngology: A Survey of Canadian Otolaryngologists. <i>The Journal of Otolaryngology</i> , 2003, 32, 239.	0.6	1